What Is Oligometastatic Disease and How Is It Treated?

Oligometastatic disease is cancer that has spread beyond where it started, but only to a small number of places in the body. Doctors see it as a middle ground between cancer that stays in one place and cancer that has spread widely.¹ Treating each spot directly, rather than relying only on drugs, may control the cancer for years and sometimes cure it in a portion of patients.² That idea has changed how many cancer teams approach a diagnosis that once meant treatment aimed only at slowing the disease.

How Many Spots Count as Oligometastatic

Leading radiation cancer groups in Europe and the US define it as 1 to 5 metastatic spots.³ The number alone is not enough, though. Every spot must be safely treatable with local treatment, such as radiation, intended to cure.⁴ There is no hard evidence for a strict maximum number of spots or organs, so the limit of five is a practical guide.⁵ The original tumor does not have to be gone, though it is often controlled.⁶

The label fits almost any cancer type and any organ the spots are in.⁷ The spots can appear at the time of first diagnosis or show up months or years after treatment.⁸ Cancer that has been shrunk down to a few spots by drug treatment is treated as its own type of oligometastatic disease.⁹ Beyond five spots, the picture is usually called polymetastatic, or widespread.¹⁰¹¹

Being called oligometastatic does not change your cancer type. It describes how far the cancer has spread.

Whether each spot is treatable matters more than the count. Two spots next to a vital structure may not qualify, while five easy-to-reach ones may. Your team weighs location, size, and your overall health, which is why two people with the same number of spots can get different advice.

Why Scans Decide Whether You Qualify

Whether cancer counts as limited depends heavily on how sensitive the scan is.¹² In women with locally advanced breast cancer, PET-CT scans found limited spread in 11% compared with 4% on standard CT and bone scans.¹³ The same PET scans also found widespread spread more often, 13% versus 7%.¹⁴ So a better scan can show a few hidden spots, or reveal that the spread is wider than thought.

For prostate cancer, a PSMA PET scan, which lights up a protein on prostate cancer cells, is the most sensitive scan for finding spots.¹⁵ It was about 27% more accurate than standard imaging in men with newly diagnosed high-risk prostate cancer.¹⁶ It can also find returning cancer while PSA blood levels are still low.¹⁷ Many men are now restaged after a PSMA scan, sometimes from localized to oligometastatic.¹⁸

Because the label depends on what a scan can see, not only on what is in the body, two people with identical cancer can be called different things depending on which scan they had. Someone labeled limited on one scan may be reclassified as widespread after a more sensitive one, which can change the plan from spot treatment to whole-body drugs. That shift is not the cancer getting worse overnight; the scan is showing more of what was already there. Before treatment planning, ask which scan your count is based on, and whether a PET or PSMA scan is available and covered for you.

Precise High-Dose Radiation Is the Main Treatment

Stereotactic body radiation therapy, often written SBRT or SABR, delivers very high doses to a small target from many angles. Each spot is treated in roughly 1 to 5 sessions rather than weeks of daily visits. It is one of the main ways to destroy spots directly, along with surgery and heat ablation.¹⁹

Planning comes first. A CT scan taken in the treatment position, sometimes fused with MRI or PET images, lets the team outline each spot precisely. Organs move as you breathe, so they use techniques such as tracking the breathing cycle or limiting how much the spot moves. Physicists and radiation doctors then design the beams so the dose is high in the spot and falls off quickly in nearby healthy tissue. That precision is why such high doses in so few sessions can be given with acceptable safety.

During a session you lie still in a molded cushion or mask so the beam hits the same place each time. It is painless, usually takes under an hour, and you go home the same day.

In a randomized trial across several cancer types with up to five spots, people given SABR lived a median of 50 months versus 28 months on standard care.²⁰ At five years, 42% of the SABR group were alive versus 18% on standard care.²¹ The time before cancer grew again doubled, from 6 to 12 months.²²

Median means half the people lived longer than that figure and half shorter. Trial patients were selected and fairly healthy, so your team will judge how the results apply to you. There was a cost: 3 of 66 people in the SABR group died from treatment effects, and larger trials are still needed to confirm the benefit.²³

Surgery to Remove the Spots

The lung and liver are the most common places doctors treat directly.²⁴ In people with bowel cancer spread to the liver or lung, 59% of those with 1 to 5 spots were alive 5 years after surgery versus 35% with six or more.²⁵ About 38% of the limited-spread group stayed cancer-free at five years.²⁶ People who needed surgery on both liver and lung did about as well as those needing one, with around 50 to 70% alive at five years.²⁷

Surgery to remove the spots is considered when every visible spot can be taken out completely while leaving enough healthy lung or liver to work well. Your overall fitness matters, including heart and lung function, because these are major operations. The surgeon also considers whether the original cancer is controlled, since removing spots while the main tumor is growing would be less useful. Spots close to major blood vessels or critical structures may suit another approach better.

Surgery gives tissue to examine and removes the spot completely. Radiation avoids cuts and suits spots that are hard to reach or people less fit for an operation. For some liver spots, radiofrequency ablation uses heat delivered through a needle. A team meeting of surgeons and radiation doctors often makes the call.

Lung or liver surgery usually means a hospital stay and weeks of recovery. Many people still need drug treatment afterward.

Results in Lung and Prostate Cancer

In people with limited spread of non-small cell lung cancer, treating all spots after initial drugs extended median survival to 41 months versus 17 months with maintenance drugs or watching.²⁸ Time before growth rose from about 4 months to 14 months.²⁹ Another small trial found that adding SABR to maintenance chemotherapy extended time before growth from 3.5 to 9.7 months.³⁰ Doctors now view local treatment as a generally safe and effective option for this group, with cure possible for some.³¹

These trials enrolled people whose cancer had responded to first drug treatment. They were small, so the findings are encouraging rather than settled. Whether local treatment suits you depends on your cancer’s genetic features, how it responded to drugs, and whether all spots are treatable.

In men whose prostate cancer came back in a few spots, treating the spots delayed the need for hormone therapy to a median of 21 months versus 13 months with watching.³² Combined long-term results show treatment roughly halves the risk of growth compared with watching.³³ Men whose tumors carried certain high-risk gene changes seemed to benefit most.³⁴

The delay matters because hormone therapy can cause hot flashes, tiredness, and bone and muscle loss. Putting it off gives more time without those effects, though it does not mean hormone therapy is avoided forever.

Combining Spot Treatment With Drug Therapy

Treating spots with precise high-dose radiation while on targeted therapy or immunotherapy has become common and is supported by guidelines.³⁵ That follows from progress in drugs: modern treatments have improved outcomes for metastatic cancer, changing where local treatment fits.³⁶

The two approaches cover different ground. Drugs reach cells that may be hiding anywhere in the body, while local treatment removes the spots large enough to see. Some people take drugs first and treat remaining spots later. If you’re on a drug, ask whether it needs pausing around radiation.

Radiation can sometimes help the immune system attack spots that were not treated, as seen in some people with melanoma on immunotherapy.³⁷ In one reported melanoma case, radiation plus immunotherapy produced a deep response even after immunotherapy alone had stopped working.³⁸ Such responses happen but are not the norm, and they are mostly reported in melanoma. Radiation should not be expected to clear spots it did not target.

Side Effects and Quality of Life

Combined trial data show quality of life changed little after precise high-dose radiation, with a small dip similar to people not given it.³⁹ When treated spots stay controlled, people tend to keep their quality of life and avoid worsening symptoms at one year.⁴⁰ Still, about 1 in 4 people had a lasting drop in quality of life within a few years.⁴¹ That drop was linked mainly to the cancer growing again and to spots in the adrenal glands.⁴²

Tiredness for a few days or weeks is common. Lung treatment can cause cough or mild breathlessness, treatment near the gut can bring nausea, and bone spots may ache briefly. Serious side effects are uncommon but can happen, such as stomach bleeding when the beam passes close to the stomach.⁴³

Risk depends mostly on what healthy tissue sits near the treated spot, so two people can have very different experiences. Spots near the stomach, bowel, or large airways carry higher risk than spots in a bone or in the outer part of the lung. Previous radiation to the same area can limit how much more can safely be given. Your team plans the dose around these limits and may choose a different approach if the risk is too high.

Black stools or vomiting blood after abdominal treatment need urgent care. New pain or breathlessness should be checked. A symptom diary makes follow-up visits more useful.

If a Few Spots Grow Later

When only a few spots grow while the rest stay controlled, doctors may treat those spots and continue the drugs that are still working.⁴⁴ In breast cancer, this controlled the treated spot in about 3 out of 4 people and delayed switching drugs by a median of about 21 months.⁴⁵ In lung cancer the benefit was smaller and not clearly proven.⁴⁶ Keeping the same drug matters because each change uses up an option.

The team checks that the growing spots can be treated safely, usually with precise high-dose radiation, and considers how long the drug has been working and how many other options remain. If growth is widespread, switching drugs is usually the better path, so it’s worth asking whether the growth is in a few spots or many before any switch.

Blood Tests That May Guide Treatment in Future

Doctors cannot yet reliably predict who will stay limited and who will develop widespread spread.⁴⁷ A blood test for tumor DNA may help spot lung cancer patients most likely to benefit from radiation.⁴⁸ Such a test may also reveal hidden spread where drugs should come first.⁴⁹ But one blood test that looked accurate failed when checked in a second group of prostate cancer patients.⁵⁰

This test is a blood draw, with no surgery. The lab looks for fragments of tumor DNA that cancer cells shed into the blood. Finding such DNA can suggest the cancer is still active, and its amount or features may hint at how widespread disease is. The test cannot show where the cancer is, so scans are still needed, and a negative result does not prove the cancer is gone, since some cancers shed little DNA.

Some centers offer these tests in clinical trials. Results may add information but should not alone decide treatment. Ask your team whether a trial fits you.

Cost and Talking About Cure

Most economic studies judge SABR good value for oligometastatic disease.⁵¹ Its value falls as more spots are treated, from about $28,000 per healthy year gained for 2 spots to $64,000 for 5.⁵²

Cost per healthy year gained estimates how much extra money buys one additional year of good health, so it compares value rather than total price. A lower figure means better value. These are model estimates that depend on assumptions about survival benefit, which larger trials may change. They also reflect healthcare systems in particular countries, so your costs may look different.

Oncologists differ on whether to use the word cure for this condition.⁵³ Ask your doctor for the full range of outcomes, from best case to worst, rather than a single estimate.⁵⁴

How many spots do I have, and can all be treated?
What do you expect from treatment: control, delay, or possible cure?
What side effects fit my spot locations?
Will I stay on drug treatment?
Am I eligible for a clinical trial?